Search results
Results From The WOW.Com Content Network
Franklin v. Parke-Davis is a lawsuit filed in 1996 against Parke-Davis, a division of Warner-Lambert Company, and eventually against Pfizer (which bought Warner-Lambert in 2000) under the qui tam provisions of the False Claims Act. [1]
Franklin and his attorney, Thomas M. Greene, filed a lawsuit, Franklin v. Parke-Davis, under the False Claims Act in federal district court in Boston. In the first off-label promotion case ever litigated in a whistleblower suit under the False Claims Act, the settlement was announced after eight years of litigation in May 2004.
Related to courtroom action were offers for a cash advance on impending settlements. Another money matter related to lawsuits and impending settlements is market timing. [24] In June 2023, GSK reached a confidential settlement for one of the lawsuits related to Zantac causing cancer. [25] [26]
Aug 17 (Reuters) - The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.
(Reuters) -Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people ...
Jun. 7—An Odessa man, his mother-in-law and his late wife's former partner have filed a wrongful death lawsuit against Revitalize Health & Wellness and a registered nurse. According to the ...
Pfizer [7] $2,300,000,000 $1 billion civil ($2.3 billion with criminal component) Off-label promotion/kickbacks: False Claims Act/FDCA 2012 4 4 (tie) Depakote: Abbott Laboratories [8] $1,500,000,000 $800 million civil ($1.5 billion with criminal component) Off-label promotion False Claims Act/FDCA 2009 5 4 (tie) Zyprexa: Eli Lilly [9 ...
Pfizer said its vaccine was 95% effective following its Phase 3 trial, but Texas' attorney general said the data was too premature. Texas AG suing Pfizer, says company misrepresented COVID vaccine ...